Stoked Bio Inc
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Stoked Bio is a translational biotechnology company established to develop new candidates for
resistant infections and cancers identified by the world-leading AI models created and implemented
in the Stokes Lab at McMaster University. Stoked Bio’s pipeline consists of structurally and
functionally novel, clinically relevant, easily synthesizable small molecules with validated
therapeutic and toxicity profiles that overcome current resistance. Stoked will be responsible for the
development of these validated candidates to preclinical validation and look to partner with
Pharmaceutical and Large Biotech companies prior to the initiation of clinical trials.
Company HQ City:
Grimsby
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2024
Lead Product in Development:
Enterololin for Hepatic Encephalopathy
CEO
Jeff Skinner
Development Phase of Lead Product
Discovery
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
Nov 2026
What is your next catalyst (value inflection) update?
Completion of Med Chem of lead product. Identification of MoA for fungal program
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}